Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome.
OBJECTIVE
To investigate the influence of inflammatory molecules in the aqueous humour and on the ocular surface on the outcome of glaucoma surgery.


METHODS
Thirty patients who needed antiglaucomatous surgery were included. The interleukin- (IL-) 8, IL-1beta, IL-6, IL-10, tumour necrosis factor- (TNF-) alpha; and IL-12 were determined from aqueous humour preoperatively and the imprints of conjunctiva were analysed for expression of human leukocyte antigen- (HLA-)-DR after surgery by flow cytometry. The success of trabeculectomy was defined as intraocular pressure less than 21 mmHg without antiglaucoma medication.


RESULTS
Eyes with trabeculectomy failure at 3 months showed significantly higher TNF-alpha and IL-6 levels in the aqueous than eyes with successful surgery. Increased expression of HLA-DR on epithelial cells and antigen-presenting cells was not associated with the trabeculectomy outcome.


CONCLUSIONS
Higher preoperative levels of TNF-alpha and IL-6 in aqueous humour may contribute to the development of inflammatory milieu and were associated with worse outcome of glaucoma surgery.
Cvenkel
Barbara
B
Eye Hospital, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
Kopitar
Andreja Natasa
AN
Ihan
Alojz
A
D000368:Aged; D001082:Aqueous Humor / Q000276:immunology*; D005123:Eye / Q000276:immunology*; D005260:Female; D005901:Glaucoma / Q000601:surgery*; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D018836:Inflammation Mediators
Ophthalmologica. 2002 May-Jun;216(3):175-9
12065853
Br J Ophthalmol. 1995 Jun;79(6):590-5
7626577
J Glaucoma. 2003 Oct;12(5):430-5
14520152
Can J Ophthalmol. 2007 Feb;42(1):89-94
17361247
Curr Opin Ophthalmol. 2005 Apr;16(2):107-13
15744141
Am J Ophthalmol. 1998 Jun;125(6):805-18
9645718
Ophthalmology. 2008 Jul;115(7):1154-1161.e4
18096232
Ophthalmology. 2004 Dec;111(12):2186-92
15582072
Ophthalmology. 2007 Oct;114(10):1831-8
17719641
J Neurosci Res. 1997 Aug 1;49(3):268-80
9260738
Am J Ophthalmol. 1996 Apr;121(4):349-66
8604728
Invest Ophthalmol Vis Sci. 1999 Mar;40(3):705-12
10067974
Br J Ophthalmol. 2006 Nov;90(11):1366-9
16809382
Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2591-9
10937571
Prog Brain Res. 2008;173:237-54
18929113
Arch Ophthalmol. 1994 Nov;112(11):1446-54
7980134
Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2659-65
9856775
Can J Ophthalmol. 2008 Jun;43(3):370
18443605
Exp Eye Res. 2004 Nov;79(5):677-88
15500826
Prog Retin Eye Res. 2004 Nov;23(6):617-37
15388077
Clin Med Res. 2006 Dec;4(4):294-309
17210978
Br J Ophthalmol. 2005 Dec;89(12):1655-9
16299150
Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2627-32
10509659
Exp Eye Res. 1994 Dec;59(6):723-7
7698265
Curr Eye Res. 2000 Feb;20(2):85-94
10617908
Ophthalmic Res. 2001 Sep-Oct;33(5):251-5
11586057
Graefes Arch Clin Exp Ophthalmol. 2003 Aug;241(8):631-6
12898279
Exp Eye Res. 2005 Jan;80(1):121-34
15652533
Ophthalmology. 2007 Oct;114(10):1822-30
17908591
Ophthalmology. 1999 Mar;106(3):556-63
10080214